stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Net income
Takeda Pharmaceutical Co.'s net income for fiscal 2026 was −$1.0B, compared with $713.7M in fiscal 2025. Over the twelve months to 30 September 2026 it was $3.2B. Over the past ten years it has ranged from −$1.3B (fiscal 2015) to $3.5B (fiscal 2021); the current reading is higher than 17% of that period. Net income has fallen for 3 consecutive fiscal years. Takeda Pharmaceutical Co. ranks 1st of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2026 | −$1.0B | — |
| FY2025 | $713.7M | (28.26%) |
| FY2024 | $995.0M | (57.59%) |
| FY2023 | $2.3B | 14.53% |
| FY2022 | $2.0B | (42.07%) |
| FY2021 | $3.5B | 767.80% |
| FY2020 | $407.5M | (58.47%) |
| FY2019 | $981.1M | (41.61%) |
| FY2018 | $1.7B | 56.42% |
| FY2017 | $1.1B | 55.04% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $1.2B | 69.93% |
| Jun 2026 | $713.5M | (49.25%) |
| Dec 2025 | $1.4B | — |
| Sep 2025 | −$92.2M | — |
| 30 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TAK Takeda Pharmaceutical Co. | $3.2B |
| HLN Haleon PLC Sponsored ADR compare | $3.1B |
| ZTS Zoetis Inc. compare | $2.6B |
| UTHR United Therapeutics Corporation compare | $1.2B |
| NBIX Neurocrine Biosciences, Inc. compare | $702.5M |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $508.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $273.0M |
| ELAN Elanco Animal Health Incorporated compare | −$199.0M |
| VTRS Viatris Inc. compare | −$607.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TAK
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement